A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) (Q82808934)
Jump to navigation
Jump to search
scientific article published on 13 March 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) |
scientific article published on 13 March 2006 |
Statements
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) (English)
C Kollmannsberger
M Schittenhelm
F Honecker
J Tillner
D Weber
K Oechsle
L Kanz
13 March 2006